|
  
- 积分
- 97
- 威望
- 97
- 包包
- 3142
|
本帖最后由 bobo 于 2009-6-28 08:34 编辑 0 s8 B4 ]/ n$ z7 Z
0 s. Z& D4 Q, W4 T8 a7 c表观遗传学与干细胞——2009年亚洲生物高峰论坛录制(音频mp3)
' n5 o$ Z9 T3 @7 ]- g$ D" A& O1 X. v; p' ]/ |* Q; S% ]$ P
3 B5 y7 O$ u3 ]; Y4 v# k
$ A1 n+ S/ `) q5 F, T( J7 I# L5 ~回复为ppt
- n% X/ ]3 F. O* {摘要：
' y8 ~ I8 k: }) t6 H/ E7 H# k, |" z5 F) H" X# p
Hongkui Deng4 |! a, [+ x2 C. o( E4 ~2 n+ t8 ?! h
- Y7 `( W \# i& G
Laboratory of Stem Cell and Generative Biology, College of Life Sciences, Peking University, Beijing 100871, China.: o; {8 g/ {) q1 k! ]2 L- L
% V$ N1 z0 w$ l C
Human pluripotent stem cells represent a potentially unlimited source of functional pancreatic endocrine lineage cells. We established a new highly efficient approach to induce human embryonic stem （ES） cells and induced pluripotent stem （iPS） cells to differentiate into mature insulin-producing cells in a chemical-defined culture system. The differentiated cells obtained by this approach comprised nearly 25% insulin-positive cells as assayed by flow cytometry analysis, which released insulin/C-peptide in response to glucose stimuli in a manner comparable to that of adult human islets. Most of these insulin-producing cells co-expressed mature beta cell-specific markers such as NKX6-1 and PDX1, indicating a similar gene expression pattern to adult islet beta cells in vivo. This work provides a new model to study the mechanism of human pancreatic specialization and maturation in vitro, and enhances the possibility of utilizing patient-specific iPS cells for the treatment of diabetes
1 ]+ \( O6 Y9 L# T/ v% V m t/ Y5 u9 J! i- \( c% V3 `* K
回复为ppt6 t! p7 ?7 e: g% ?5 ?5 T
2 O% q" X3 m# `8 Z3 n/ c2 ~4 c) M1 q0 L( G5 _
/ ] I, ~9 c! x
" N) j/ |. p, r6 ?, { |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
|
发表于 2009-6-28 08:19
发表于 2009-8-7 16:10
